A Medical Device Daily

Phase Forward (Waltham, Massachusetts), a provider of data management solutions for clinical trials and drug safety, reported a multi-year, multi-million dollar license and services agreement with Novo Nordisk (Princeton, New Jersey), expanding their existing relationship.

Novo Nordisk said it plans to use Phase Forward's InForm electronic data capture (EDC) product as the default system across all clinical trial phases, from Phases I through IV.

Since signing an application service provider (ASP) arrangement in mid-2006, Novo Nordisk said it has integrated global InForm studies with internal systems. Novo Nordisk said it is now using InForm to support trials in more than 30 countries.

Henrik Lynge, head of Clinical System Management at Novo Nordisk, said, "InForm's ability to easily integrate with other in-house systems and the product's scalability have been crucial to the implementation ..."

In other agreements and contracts news:

• SunTech Medical (Morrisville, North Carolina) reported a partnership with Medifacts International (Rockville, Maryland) for the SunTech 247 Diagnostic Station to be included in Medifacts' clinical hemodynamic capabilities.

The SunTech 247, an automated office blood pressure (BP) monitor with optional temperature and pulse oximetry modules, will be used by Medifacts to provide clinical grade BP monitoring, enabling small- or large-scale clinical trials in clinic and home environments. SunTech said it also will provide the company with additional telemedicine capabilities in the future.

• Revolutions Medical (Mount Pleasant, South Carolina) reported signing a worldwide exclusive license with Strategic Product Development (SPD) for an image guided navigation system that incorporates breast biopsies system (BBS) to conventional mammography systems numbering more than 50,000 globally.

The technology, which has received FDA 510(k) clearance, is designed to facilitate the localization of non-palpable lesions and micro-calcifications localizations for treating breast cancer.